Water, glycerin, BG (butylene glycol), glycereth-26, PEG/PPG/polybutylene glycol-8/5/3 glycerin, betaine, Human adipose-derived mesenchymal cell exosomes, glutathione, arbutin, lecithin, Linseed fatty acid, tocopherol acetate, ascorbyl palmitate, human recombinant oligopeptide-1,Ceramide AP, ceramide NP, atelocollagen, hydroxypropyltrimonium hyaluronate, tocopherol, Jojoba seed oil, olive fruit oil, sunflower seed oil, dipotassium glycyrrhizinate, ionized sugar Polyglyceryl-10 isostearate, PEG-75, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, Xanthan gum, citric acid, sodium citrate, disodium EDTA, propanediol, phenoxyethanol, methylparaben
Retatrutide Background Retatrutide (LY3437943) is the first GLP-1/GIP/GCG triple agonist to complete phase 2 trials, with phase 3 studies ongoing for obesity and/or T2D management
[DOI] [PubMed] [Google Scholar] 51.Kamande J.W., Nagendran T., Harris J., Taylor A.M
Mediterranean diet protects against a neuroinflammatory cortical transcriptome: associations with brain volumetrics, peripheral inflammation, social isolation, and anxiety in nonhuman primates ( Macaca fascicularis )
Without peer-reviewed human data, assertions of efficacy or safety stand primarily on animal studies, case reports, and anecdote
Brain Behav Immun (2018) 73:3109
